Publications by authors named "D M Lui"
Background: High levels of high-density lipoprotein cholesterol (HDL-C) are previously considered protective against cardiovascular diseases (CVD), but recent studies suggest an increased risk of adverse events at very high HDL-C levels in the general population. It remains to be elucidated such a relationship in diabetes, a condition with high cardiovascular risks. We examined the association of HDL-C levels with the risk of major adverse cardiovascular events (MACE) and mortality in type 2 diabetes.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effects of combining pioglitazone, GLP1RA, and SGLT2i on metabolic dysfunction-associated steatohepatitis (MASH) in patients with type 2 diabetes.
- Results from 888 patients showed that using more of these medications correlated with significant improvements in liver health, as measured by changes in the FAST score over a median follow-up of 3.9 years.
- Specifically, the combination of SGLT2i and pioglitazone was associated with the highest likelihood of achieving better FAST score outcomes, suggesting a promising approach for managing MASH in diabetic patients.
Associations of Serum Lipid Traits With Fracture and Osteoporosis: A Prospective Cohort Study From the UK Biobank.
J Cachexia Sarcopenia Muscle
December 2024
Background: Previous studies reveal inconsistent associations between serum lipid traits and the risks of fractures and osteoporosis in the general population.
Methods: This prospective cohort study analysed data from 414 302 UK Biobank participants (223 060 women and 191 242 men, aged 37-73 years) with serum lipid measurements: apolipoprotein A (Apo A), apolipoprotein B (Apo B), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), triglycerides (TG) and lipoprotein A (Lp(a)). Multivariable Cox proportional hazard models with penalized cubic splines were used to explore potential nonlinear associations of each lipid trait with the risks of fractures and osteoporosis.
Purpose: Naltrexone-bupropion (Contrave®) has shown efficacy and safety in large randomised controlled trials, predominantly comprising Caucasians. Data are limited in Asian populations. We carried out a retrospective matched cohort study of Chinese patients with obesity to evaluate the efficacy and safety of naltrexone-bupropion in real-world clinical practice.
View Article and Find Full Text PDF